...
首页> 外文期刊>Journal of vascular surgery >Early and midterm outcome of a novel technique to simplify the hybrid procedures in the treatment of thoracoabdominal and pararenal aortic aneurysms.
【24h】

Early and midterm outcome of a novel technique to simplify the hybrid procedures in the treatment of thoracoabdominal and pararenal aortic aneurysms.

机译:一种新型技术的早期和中期结果,简化了治疗胸腔的杂交程序和伞形主动脉瘤。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: To evaluate the effectiveness of the Viabahn Open Revascularization Technique (VORTEC) in the treatment of thoracoabdominal aortic aneurysms (TAAAs) and pararenal aortic aneurysms (PAAAs) by hybrid procedures. METHODS: Between December 2004 and March 2009, 58 patients (45 male, mean age, 74 years) were diagnosed with TAAA (n = 30) and PAAA (n = 28) and treated electively by combined hybrid techniques. Hybrid procedure includes bypass surgery of the visceral and renal arteries (debranching or rerouting), followed by endovascular exclusion of the aortic aneurysm. One hundred thirteen renovisceral vessels were revascularized in a retrograde fashion (ie, 98 renal and 15 visceral arteries), using VORTEC. The novel technique consists of the placement of self-expanding stent-grafts (Viabahn graft, Gore and Associates, Flagstaff, Ariz) in Seldinger technique into the renal and visceral arteries after surgical identification of the origin of the arteries. The end of the stent outside of the renal artery was sutured end to side directly with the main feeding graft, bypassing the aneurysm, or was fixed into an interposition branch graft on the main bypass. All cases were treated by two-staged approach (endovascular aneurysm repair [EVAR] performed after recovery from the debranching procedure). Computed tomography angiography and clinical follow-up were obtained before discharge, at six weeks, and three, six, and 12 months after the procedure and then annually. RESULTS: Primary technical success of VORTEC was achieved in all patients. Overall primary patency rate of the novel technique was 97% during a mean follow-up of 22.1 +/- 12.9 months (range, 1-52 months); the primary patency of the subgroups PAAAs and TAAAs was 97.7% and 96.4%, respectively; the assisted primary patency rate was 98%, as two occluded Viabahn grafts were reopened by thrombolysis and thrombus aspiration. No patient required long-term hemodialysis. Thirty-day mortality rate was 8.6% (5/58) and 25.8% (15/58) for the entire follow up. Permanent neurologic deficit occurred in two cases (3.4%; paraplegia, n = 1; paraparesis, n = 1). The overall endoleak rate was 17.1% as three patients presented early (30-day) type I endoleak, treated by cuff-implantation, and six patients presented type II endoleak, three of them treated by coil embolization of the patent vessel and the others treated conservatively with radiological surveillance. CONCLUSION: VORTEC allows performance of easy, safe, and minimally invasive revascularization of renal and visceral arteries and may represent a significant technical advance in the hybrid repair of TAAAs and PAAAs. However, the questions of reproducibility by other centers and long-term results are mandatory to establish this alternative revascularization option.
机译:背景:为了评估在胸腹主动脉瘤(TAAAs),并通过混合程序肾旁主动脉瘤(PAAAs)的治疗中Viabahn打开血运重建技术(VORTEC)的有效性。方法:2004年12月和2009年3月间,58名患者(45男,平均年龄74岁)被诊断患有TAAA(N = 30)和PAAA(N = 28)和结合混合技术处理择。混合过程包括内脏和肾动脉(脱支或重新路由)的旁路手术,随后主动脉瘤的血管内排除。百个13 renovisceral船只以逆行方式进行再血管化(即98肾脏和15周内脏动脉),用VORTEC。该新颖技术包括自扩张支架移植物放置的(Viabahn接枝,戈尔联合,旗杆,亚利桑那州)的Seldinger技术进入肾和内脏动脉外科识别血管起源的后。肾动脉的支架外侧的端部被缝合端直接与主馈送接枝到另一侧,绕过动脉瘤,或固定到主旁路的插入分支移植物。所有病例均经两级方法(血管内动脉瘤修复[EVAR]从脱支过程恢复之后执行)处理。出院前获得了计算机断层扫描血管造影和临床随访,6周和三,六,并在手术后12个月,然后每年。结果:VORTEC的主要技术成功在所有患者中实现。该新颖技术的整体主通畅率为期间97%的平均随访22.1 +/-12.9个月(范围,1-52个月);亚组PAAAs和TAAAs的初级通畅分别为97.7%和96.4%;的辅助初级通畅率为98%,为两个闭塞Viabahn移植物通过溶栓和血栓抽吸重新打开。没有病人需要长期进行血液透析。三十天的死亡率为8.6%(5/58)和25.8%(58分之15)整个跟进。永久性神经缺陷发生在两种情况下(3.4%;截瘫,N = 1;下肢轻瘫,N = 1)。整体内漏率分别为17.1%为三名患者呈现早期(30天)I型内漏,通过袖带注入处理,六名患者呈现II型内漏,其中三个由专利容器的线圈栓塞治疗和其它治疗保守与放射性监测。结论:VORTEC使肾和内脏​​动脉的方便,安全,微创血管重建的性能和可代表TAAAs和PAAAs的混合修复显著的技术进步。然而,重复性的其他中心和长期效果的问题是必须建立这种替代血运重建选项。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号